Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Zooming with LD (July 2020)
14 slides from Streamex's conference presentation, Jul 27, 2020
Slide 1: BioSig Technologies - Zooming with LD
BioSig technologies BioSig Technologies Ken Londoner, Founder, Chairman and CEO Zooming with LD July 27", 2020 - NaspaQ: BSG Zao¢ BloSio
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: BioSig Technologies Positioned for Success
BioSig Technologies Positioned for Success ————* Nluiti-illion dotiar etectrophysiology (EP) market ——® Demand driven by high prevalence of arhythmia + Procedures more efficacious than drugs, predicated on abiliy to analyze clean cardiac signals, ——————* Differentiated value proposition and impact t
Slide 4: Strong Performance by both MedTech and Pharmaceutical Divisions
Strong Performance by both MedTech and Pharmaceutical Divisions First-class industry experience Robust financial performance + Growing team of experienced clinical and commercial specialists Stock up 34% yearto-date Significantly outperformed Dow and Russell 2000 + Conducting daily patient cases wit
Slide 5: PURE EP
PURE EP" PURE EP™ at-a-glance seo cs | real-time signal p orm engineered to re cd : non-invasive platform technology provides detailed intracardiac information acquisition of high-fidelity cardiac analog signals in an original unfiltered format : demonstrated ability to maintain signal integrity eve
Slide 6: PURE EP Developed Through Collaboration with Leading Centers
PURE EP™ Developed Through Collaboration with Leading Centers Relationships at leading, high-volume centers create traction for PURE EP™ in the market 2014 2013 2014 2014 2015 2016 a Concept developed Proof of concept, Prototype test Initial pre-clinical First pre-clinical Advanced research with Tex
Slide 7: Driving Market Awareness Through Physician Insights
Driving Market Awareness Through Physician Insights APR 2020: EP Lab Digest Interview with Andrea Natale, M.D. ~ MAY 2020: Stanford Arrhythmia Symposium Presentation by Mayo Clinic on shortcomings in EP and how PURE EP™ is addressing them (audience of ca. 320 physicians) AF Spotlight Session PURE EP
Slide 8: Defining the Market Opportunity
Defining the Market Opportunity Global Growth in EP Devices: $4.5B in 2017, projected to reach $7.4B in 2022 10.4% growth rate Global Growth Ous: in Complex Cardiac Ablation 3,729 hospitals averaging Procedures: 1.05 rooms per lab i3 Bae 2017 to aah in 2022 3,915 0% growth rate s EP room EP rooms Da
Slide 9: As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19?
As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19? EP procedures are clinically urgent Reimbursement rates continue to Increase Delaying procedure increases stroke risk and worsens outcomes EP procedures are revenue generat CMS Reimbursement Changes Fr
Slide 10: COVID-19 Asset Developed by Subsidiary, ViralClear Pharmaceuticals
COVID-19 Asset Developed by Subsidiary, ViralClear Pharmaceuticals + Merimepodib, lead compound, currently in Phase ll clinical trial for COVID-19 = Broad-spectrum, orally administered anti-viral previously tested in other indications — Commenced Phase II clinical trial in June 2020 at Mayo Clinic u
Slide 11: Unique Collaboration with Mayo Clinic
Unique Collaboration with Mayo Clinic + 0-year strategic agreement ~ Collaboration on technology development Joint IP filings ~ Licensing opportunities MAYO Mayo Clinic has invested capital in the development of the PURE EP™ System. CLINIC + Phase II clinical trial support for ViralClear Pharmaceuti
Slide 12: Key Milestones
Key Milestones 2020 2021 5 o/ Targeted commercial release of PURE EP™ System o Accelerate commercialization of PURE EP™in US. ou Deliver Phase Ill results for COVID-49 therapy Obtain top line Phase II clinical data for merimepodib ov File further IP, advance R&D in bioelectronic medicine o Initiate
Slide 13: Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization
Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization Kenneth L. Londoner, MBA Foundor, Chalman, £0, Dicctor NoureCtoorTezholegies:iatCoor Pharmacoutens: Enaleatt Managamont Partners J &\W Salman & Co ‘Stove Chaussy, CPA Natasha Drapeau eo vceutne es Pr
Slide 14: Business Model Summary
Business Model Summary Highlights: + PUREEP™ System expected to generate revenue beginning in H2 2020 © Decreasing annual cash buen in 2020 © Scaling up organization through increasing salesforce and extending, relationships with world-class healthcare institutions + Robust commercial strategy led b